• ECL Western Blotting Substrate: Practical Guide

  2026-09-08

  ECL Western Blotting Substrate (SKU K2187) is a luminol-based horseradish peroxidase detection reagent for sensitive, nonradioactive protein detection by chemiluminescence in immunoblots. It is intended for HRP-based Western blot assays and should not replace fluorescent or radioisotopic detection reagents.

• SB-505124 Hydrochloride: A Causal Assay Tool

  2026-09-08

  SB-505124 hydrochloride enables reversible dissection of ALK4, ALK5, and ALK7 signaling in fibrosis and cancer mechanobiology. This article shows how to pair pathway inhibition with stiffness, cytoskeletal, and immune-cell assays without confusing correlation with mechanism.

• Dorsomorphin: AMPK, BMP, and Nrf2 Assay Design

  2026-09-07

  Dorsomorphin (Compound C) enables controlled interrogation of AMPK and BMP signaling, but its interpretation changes under viral oxidative stress. This guide develops a redox-aware assay strategy grounded in Nrf2 time-course biology and practical pathway controls.

• Dorsomorphin (Compound C) Research Workflow

  2026-09-07

  Dorsomorphin, also called Compound C, provides a rapid, reversible way to interrogate AMPK-dependent metabolism, autophagy, and differentiation while also exposing BMP pathway biology. This workflow combines phospho-signaling controls, dose optimization, macrophage-inflammation readouts, and safeguards against confounding AMPK-independent BMP effects.

• Crizotinib in Patient-Derived Cancer Assembloids

  2026-09-05

  A translational framework for using Crizotinib hydrochloride to connect ALK, c-Met, and ROS1 pathway biology with patient-derived gastric cancer assembloids, stromal modulation, and resistance-aware drug testing.

• DMH1: ALK2 Inhibitor Workflows for Organoids

  2026-09-04

  DMH1 provides a selective way to interrogate BMP-dependent fate decisions in human intestinal organoids while supporting mechanistic non-small cell lung cancer research. This guide connects pathway validation, practical dosing, migration assays, and troubleshooting to reproducible experimental workflows.

• WY-14643: PPARα Workflows for Liver Research

  2026-09-04

  Build more informative PPARα experiments with WY-14643 by linking receptor activation to lipid metabolism, endothelial inflammation, and YAP-TEAD-dependent liver regeneration. This practical guide separates reference-backed dosing from assay optimization recommendations and provides troubleshooting steps for reproducible results.

• PVT VGluT2 Neurons Link Parkinson’s Disease to Depression

  2026-09-03

  This study identifies VGluT2-positive neurons in the paraventricular thalamic nucleus as a circuit-level driver of depression-related behaviors in paraquat-induced Parkinson’s disease. By combining cell-type-specific chemogenetic manipulation with projection and synaptic analyses, it connects PVT activity to glutamatergic and structural changes in the central amygdaloid nucleus, separating affective pathology from motor dysfunction.

• TSSK2 Inhibitors: Pyrimidine SAR and Male Contraception

  2026-09-03

  Hawkinson and colleagues identified the first sub-100 nM inhibitors reported for most TSSK isoforms by combining a mobility-shift high-throughput screen with pyrimidine and pyrrolopyrimidine medicinal chemistry. The study highlights TSSK1/2 dual inhibition as a rational direction for reversible male contraception while also defining the biochemical evidence and selectivity limitations that must precede cellular and in vivo validation.

• SB 431542 in Neuroimmune TGF-β Research

  2026-09-02

  Explore how SB 431542, a selective ALK5 inhibitor, can convert emerging MMP8–TGF-β findings in enteric neuronal injury into rigorous causal assays. This guide emphasizes pathway validation, exosome-aware controls, and interpretation limits rather than routine pathway description.

• SMPD4, Ceramide, and Primary Cilia Development

  2026-09-02

  The 2024 Development study combines a mouse loss-of-function model with SMPD4-deficient human induced pluripotent stem cells to connect sphingomyelin metabolism, ceramide production, primary-cilium integrity, and brain development. Its ceramide-rescue experiment provides a mechanistic framework for understanding microcephaly, neural progenitor loss, and cerebellar hypoplasia.

• SB525334 in TGF-beta1 Receptor Workflows

  2026-09-01

  SB525334 enables selective interrogation of ALK5-driven Smad2/3 signaling across fibrosis, renal disease, and wound-repair models. This workflow connects the compound’s biochemical selectivity with the bone-transport study’s angiogenic and osteo-immune findings while clearly separating validated evidence from assay-development recommendations.

• SMYD2 Inhibition in Cisplatin-Induced Renal Fibrosis

  2026-09-01

  The reference study identifies SMYD2 as a pharmacologically tractable regulator of cisplatin-induced renal injury, fibrosis, epithelial–mesenchymal transition, and inflammation. By combining AZ505 and LLY507 treatment in a renal disease model with tubular epithelial-cell experiments, the work connects SMYD2 activity to Smad3-, STAT3-, and Smad7-associated signaling and provides a framework for mechanistic epigenetic regulation research.

• A20, Oxidized Self-DNA, and Acute Kidney Injury

  2026-08-31

  The reference study identifies oxidized self-DNA as an inflammatory driver in acute kidney injury and shows that A20 limits damage by suppressing STING signaling and NEK7-dependent NLRP3 pyroptosis. Its combination of patient and mouse evidence, genetic perturbation, and peptide rescue highlights a mechanistically defined route for AKI research while keeping broader disease applications appropriately hypothesis-driven.

• CCT007093: Practical PPM1D Inhibition Workflows

  2026-08-31

  Learn how CCT007093 (SKU B3274) can support reproducible viability, proliferation, and pathway studies involving PPM1D and p38 MAPK. This scenario-based guide covers model selection, DMSO handling, timing, controls, interpretation, and practical vendor evaluation.

8031 records 1/536 page Next 12345 下5页 Last page